Declaretimi 58 Supports Hf Benefit Of Sglt2 Inhibitors | Latest News RSS feed

Declaretimi 58 Supports Hf Benefit Of Sglt2 Inhibitors - Latest News


DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

CHICAGO, IL—DECLARE-TIMI 58, a trial of the selective sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga; AstraZeneca) in patients with type 2 diabetes and high cardiovascular ... read more

DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes?

"The renal outcome data will also be important and is eagerly awaited, given the strong evidence of benefit for this in the previous trials," Perkovic stressed. In the company press release, ... read more

First sub-analyses from the DECLARE-TIMI 58 trial further support the cardiovascular effects of Farxiga in type-2 diabetes

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that ... including heart attack, or heart failure.” Farxiga is a selective inhibitor of human ... read more

Looking for another news?


Low EF Heart Failure Benefits Most From SGLT2 Diabetes Drug

NEW ORLEANS -- Heart failure benefits with dapagliflozin (Farxiga ... Source Reference: Verma S, McMurray JJV "The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights from ... read more


Cardiovascular benefits of diabetes drug extend across a wide spectrum of patients, shows study

The cardiovascular benefits ... stem from the DECLARE-TIMI 58 trial, which reported in 2018 that dapagliflozin, part of a class of drugs known as SGLT2 inhibitors, reduced the composite primary ... read more

Diabetes drug effective against heart failure in wide spectrum of patients

Other ongoing trials are investigating SGLT2 inhibitors in patients with heart failure, which should shed further light on the benefits observed in this study, Kato said. DECLARE-TIMI 58 was funded by ... read more

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

NEW ORLEANS, LA—Two new analyses from the DECLARE-TIMI 58 ... an SGLT2 inhibitor should be strongly considered as part of routine secondary prevention. In these individuals, SGLT2 inhibitors will ... read more

Diabetes drug effective against heart failure in wide spectrum of patients

The cardiovascular benefits ... stem from the DECLARE-TIMI 58 trial, which reported in 2018 that dapagliflozin, part of a class of drugs known as SGLT2 inhibitors, reduced the composite primary ... read more

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

I think after the DECLARE-TIMI 58 trial we can definitely now say the biggest benefit of the SGLT2 inhibitors is on the prevention of heart failure, and the reduction in major cardiovascular events is ... read more

Jardiance May Help Heart by Shifting Its Fuel

The SGLT2 inhibitor empagliflozin (Jardiance ... Since the trial's release in 2015, the class effect of reduced heart failure hospitalization by SGLT2 inhibition has been confirmed in the CANVAS and ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us